Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | PHGDH | O43175 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9093997 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL11705681 | 0.82 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL11702721 | 0.79 | KMT2A (0.54) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL27765617 | 0.77 | MAPT (0.61) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL956221 | 0.71 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL12476611 | 0.71 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL2224538 | 0.70 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL11705785 | 0.70 | NPC1 (0.61) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL11702729 | 0.70 | PTGS2 (0.49) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL11708161 | 0.69 | RAB9A (0.53) | ALDH1A1KMT2AMEN1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643299-B1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA SA (ES) | 2016-06-22 | — | — | EP | disclosed |
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6489324-B2 | TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020128270-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0948489-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998027069-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128270-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP1, MMP2, TNF | ALDH1A1 151/4885PHGDH 2561/4885KMT2A 1602/4885 |
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | ALDH1A1 281/4885PHGDH 2645/4885KMT2A 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.